Bertis Inc.
Address : 3rd floor, B Building, 33, Gwacheon-daero 7-gil, Gwacheon-si, Gyeonggi-do, Republic of Korea
General : contact@bertis.comIR : ir@bertis.comMedia : communication@bertis.com
NEWSROOM
Read latest news from Bertis
Bertis-NCCRI signed an R&D MoU for the development of proteomics-based cancer diagnosis, treatment
Date 2021.12.07 Hit 1,967 News |
---|
Bertis-National Cancer Center Research Institute signed an R&D MoU for the development of proteomics-based cancer diagnosis and treatment
- An agreement with National Cancer Center Research Institute (NCCRI) to develop proteomics-based biomarker research, next-generation cancer diagnosis, and treatment - Bertis CEO Seung Man Han announced, “The company will attribute to healthcare by contributing to research and development with the accumulated core technology and know-how as a leading proteomics company”
<A non-face-to-face business agreement ceremony Bertis-NCCRI on 3rd December 2021 (NCCRI director Young Woo Kim and Bertis CEO Seung Man Han)>
Bertis, a proteomic-based precision medicine development company, announced 7th December 2021 that the company signed a memorandum of understanding (MoU) with NCCRI for ‘co-research and development of proteomic-based cancer diagnosis and the treatment’.
For the agreement, both parties plan to actively cooperate on conducting clinical trials for cancer diagnosis and treatment and development of proteomic-based biomarker discovery from several types of cancer tissues and blood samples.
The basis of the joint R&D, proteomics, which attracts public attention as a key to precision medicine for early diagnosis and personalized treatment, is a diagnostic technology that analyzes the function and structure of proteins to study the mechanism and therapeutics of diseases.
Based on the MoU, both organizations plan to initiate joint research and clinical trials for the development of cancer diagnosis and treatment by promoting mutual exchanges of core technologies of quantitative proteomics from Bertis and cancer research capabilities from NCCRI.
Bertis CEO Seung Man Han said, “We are happy to work with NCCRI, which plays a leading role in cancer research based on world-class data and technology” and told, “Our company will do the best to contribute to research and development by sharing accumulated know-how and core technology as a leading proteomics company to fight cancer, which is the highest cause of death in South Korea”
Bertis has built 25 million protein libraries through research over the past decade and is developing multi-marker diagnostic technologies for various diseases. The company has commercialized the blood test-based world’s first proteomic-analytic breast cancer early diagnosis solution called “MASTOCHECK” and further widened its service over a cancer diagnosis, including pancreatic cancer and ovarian cancer.
In addition, the company is trying to accelerate precision medicine by developing markers for personalized treatment and coalesce databases based on treatment mechanisms built from quantified libraries and patient protein information. |